Trial Profile
Randomized, Multicenter Phase II Study of Pembrolizumab in Combination With Chemotherapy and Chemoradiation in Locally Advanced Esophageal Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 30 May 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Dec 2023.
- 06 Jun 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2023.
- 22 Sep 2021 Planned number of patients changed from 46 to 42.